Close Menu

NEW YORK (GenomeWeb) – Gene editing technology company Inscripta said today that it plans to acquire Solana Biosciences, a life sciences company founded in 2017 by former Illumina employees.

The acquisition will help accelerate the commercialization of Inscripta's gene editing tools by assembling a life science product development and manufacturing pipeline for precision gene editing, the firm said. Terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times Magazine examines gender discrimination at the Salk Institute.

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.